Shareholders Approve SeraCare Sale to Private Equity Firm | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SeraCare Life Sciences shareholders have approved the $82 million sale of the firm to private equity firm Linden Capital Partners, SeraCare announced today.

Under the terms of the deal, originally announced in February, holders of outstanding shares of SeraCare's common stock will receive $4 per share. The deal is expected to close on Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.